Creating a new treatment to improve blood production in patients with specific blood disorders
Official title: Developing an inhibitor of EIF2AK1 to overcome ineffective erythropoiesis in myelodysplastic syndromes with ringed sideroblasts
Funded at University of Tx Md Anderson Can Ctr · NIH-10726479 · Data updated 2026-11-12
This study is testing a new medication that could help improve blood cell production for patients with myelodysplastic syndromes and ringed sideroblasts, aiming to reduce anemia and the need for blood transfusions.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $378,674 |
| NIH project number | 1R21CA283679-01 |
| Project ID | NIH-10726479 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with myelodysplastic syndromes, particularly those with mutations in the SF3B1 gene and who experience severe anemia.
✕Less likely to help
Patients without myelodysplastic syndromes or those who do not have the specific SF3B1 mutation may not benefit from this research.
What this research studies
This research focuses on developing a new small-molecule inhibitor that targets EIF2AK1, a protein involved in the regulation of blood cell production, specifically for patients with myelodysplastic syndromes characterized by ringed sideroblasts. The study aims to address the ineffective erythropoiesis, or blood cell production, that many patients experience, which often leads to severe anemia and the need for frequent blood transfusions. By inhibiting EIF2AK1, the researchers hope to enhance the differentiation of blood cells and reduce the dependency on transfusions. The research will involve testing this inhibitor in samples from patients with specific genetic mutations associated with their condition.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that improves blood production and reduces the need for blood transfusions in patients with myelodysplastic syndromes.
How similar studies have gone: Previous studies have shown promise in targeting similar pathways for improving blood production, but this specific approach is novel and has not been extensively tested.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Colla, Simona — University of Tx Md Anderson Can Ctr
- Study coordinator: Colla, Simona
Related research
Other NIH-funded projects on the same topics.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Whole-genome sequencing to refine risk in myelodysplastic syndromes (MDS) for older adults
This project uses clinical whole-genome sequencing to improve genetic profiling and better predict how MDS will progress in older patients.
-
Targeting gasdermin D to treat myelodysplastic syndromes in people with bone marrow inflammation
A research project aims to find new ways to treat myelodysplastic syndromes by blocking a protein (gasdermin D) involved in harmful bone marrow inflammation.
-
Understanding why some MDS patients relapse after a stem cell transplant
A study of patients with myelodysplastic syndromes after stem cell transplant to learn the cellular changes and gene activity that lead to relapse, with the goal of guiding future treatments.
-
Risk factors and inflammation biomarkers for cardiovascular disease in older adults with myelodysplastic syndromes
A study focuses on older adults with myelodysplastic syndromes to understand why they have higher cardiovascular risk and how inflammatory proteins in the blood might help predict it.
-
Therapeutic targeting of transcription-epigenetic defects in SF3B1-mutant MDS
A training-focused grant to help a clinician-scientist develop therapies for adults with a common bone marrow failure condition called SF3B1-mutant myelodysplastic syndrome (MDS).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.